ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, 2005 Rational Pharmaceutical Management Plus

Date of Data Collection Source of Information Country Date of Data Collection Population Cote d'Ivoire Sept 2005 Adults Ethiopia July 2005 Haiti December ‘04 to July 2005 Adults and Pediatrics Kenya Namibia March 2005 Rwanda August 2005 Zambia

Limitations Data Collected from selected countries may not be representative of total population treated in countries and may include non-PEPFAR supported patients Data not available on rate of switch from 1st- to 2nd-line regimens All reported regimens included in analysis of 1st-line ARV distribution All regimens, except for WHO 1st-line regimens, considered in analysis of 2nd-line ARV distribution Ritonavir was excluded in analysis Some pediatric regimens may have been counted as adults Pediatric regimens not organized by formulation taken-data not available

Summary of Data Collected Total number of patients: 77,378 Adult patients: 71,550 Pediatric patients: 5,828 Total number of adult regimens: 76 Total number of pediatric regimens: 31

Percentage of Adult Patients on WHO 1st-line Regimens

Percentage of Pediatric Patients on WHO 1st-line Regimens

Percentage of Adult ART Regimens with NRTIs only

Percentage of Pediatric ART Regimens with NRTIs only

Distribution of ARVs in 1st-line Regimens % in Adult Regimens % in Pediatric Regimens 3TC 97.8% 98.7% D4T 71.5% 43.8% ZDV 27.7% 55.7% TDF 0.29% — EFV 26.3% 27.1% NVP 70.6% 69% ddI 2.4% 0.84% ABC 0.71% 1.37% PIs 2.61% 2.99% LPV/r 0.85% 2.95% NFV 0.69% 0.02% IDV 1.06% SQV/r 0.01%

Distribution of ARVs in 2nd-line Regimens % in Adult 2nd-line Regimens % in Pediatric 2nd-line Regimens ddI 51.2% 17.8% ABC 15% 29% TDF 6.26% — PIs 55.7% 63% IDV 22.52% 0.36% LPV/r 18.17% 62.32% NFV 14.69% SQV/r 0.15% (ZDV, D4T, 3TC, EFV and NVP have been excluded)